NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Liposomal cytarabine and daunorubicin for untreated acute myeloid leukaemia [ID1225]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

# Consultation

|  |
| --- |
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| During the scoping process it was agreed that the committee should discuss whether there are any equality issues surrounding age. This issue was raised at the committee meeting. Because the recommendation for liposomal cytarabine and daunorubicin is for the whole population in the anticipated marketing authorisation, the committee concluded that its recommendations do not have a different impact on people protected by the equality legislation than on the wider population. |

|  |
| --- |
| 1. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| The issues surrounding age were raised again in the submissions. This was addressed by the committee as described in section 1. |

|  |
| --- |
| 1. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
| No other potential equality issues were raised by the committee. |

|  |
| --- |
| 1. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| No. |

|  |
| --- |
| 1. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No. |

|  |
| --- |
| 1. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE’s obligations to promote equality? |
| N/A |

|  |
| --- |
| 1. Have the committee’s considerations of equality issues been described in the appraisal consultation document, and, if so, where? |
| Yes, in section 3.15. |

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 15/08/2018

# Final appraisal determination

(when an ACD issued)

|  |
| --- |
| 1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these? |
| No additional potential equality issues were raised during consultation. |

|  |
| --- |
| 1. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group? |
| The recommendation is for the whole population in the marketing authorisation so it does not have a different impact on people protected by the equality legislation than on the wider population. |

|  |
| --- |
| 1. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability? |
| No. |

|  |
| --- |
| 1. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE’s obligations to promote equality? |
| No. |

|  |
| --- |
| 1. Have the committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where? |
| Yes, in section 3.14. |

**Approved by Associate Director (name):** Jasdeep Hayre

**Date:** 18/12/2018